Physician profile
Saima Saeed
NPI 1124054390
$1,905.37
in general payments reported to CMS, 2019-2025
31 companies · $28.31 in 2025
The $28.31 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,591 · 2020: $231 · 2024: $55.27 · 2025: $28.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $210.25 | 2019-2020 | |
| Pfizer INC. | $202.25 | 2019-2020 | |
| Janssen Biotech, INC. | $159.97 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $152.56 | 2019-2020 | |
| Lilly USA, LLC | $144.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.60 | 2019-2020 | |
| Abbvie INC. | $97.76 | 2019-2025 | |
| Genzyme Corporation | $89.92 | 2019 | |
| Merck Sharp & Dohme LLC | $82.65 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $74.50 | 2019 | |
| Celgene Corporation | $74.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $54.54 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $38.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.86 | 2019-2020 | |
| Seagen INC. | $35.78 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $33.91 | 2019 | |
| Array Biopharma INC | $33.64 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $31.48 | 2019 | |
| Dendreon Pharmaceuticals LLC | $26.84 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.06 | 2019 | |
| Kyowa Kirin, INC. | $22.84 | 2019 | |
| Advanced Accelerator Applications | $22.64 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $22.13 | 2019 | |
| Exelixis INC. | $17.55 | 2019 | |
| Genentech USA, INC. | $17.39 | 2019 | |
| Blueprint Medicines Corporation | $17.19 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.49 | 2019 | |
| Astellas Pharma US INC | $13.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.59 | 2019 | |
| Daiichi Sankyo INC. | $10.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.